Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The evaluated boxed-warning topics in the AI response are directly supported by the provided FDA prescribing information excerpts for XANAX (alprazolam), with no contradictions.
Category Scores
Accurate Statements
Concomitant use with opioids may result in profound sedation, respiratory depression, coma, and death.
Section 5.1: “Concomitant use of benzodiazepines, including XANAX, and opioids may result in profound sedation, respiratory depression, coma, and death.”
Concomitant opioid analgesics and benzodiazepines increase risk of drug-related mortality compared to opioids alone.
Section 5.1: “Observational studies have demonstrated that concomitant use of opioid analgesics and benzodiazepines increases the risk of drug-related mortality compared to use of opioids alone.”
Benzodiazepines including XANAX expose users to risks of abuse, misuse, and addiction that can lead to overdose or death.
Section 5.2: “The use of benzodiazepines, including XANAX, exposes users to the risks of abuse, misuse, and addiction, which can lead to overdose or death.”
Physical dependence can occur and abrupt discontinuation or rapid dosage reduction may precipitate acute withdrawal reactions that can be life-threatening (e.g., seizures).
Section 5.3: “Abrupt discontinuation or rapid dosage reduction of XANAX… may precipitate acute withdrawal reactions, which can be life-threatening (e.g., seizures).” and Section 9.3: “Abrupt discontinuation or rapid dosage reduction… may precipitate acute withdrawal reactions, including seizures, which can be life-threatening.”
Using a gradual taper reduces risk of withdrawal reactions.
Section 5.3: “To reduce the risk of withdrawal reactions, use a gradual taper to discontinue XANAX or reduce the dosage.” and Section 9.3: same concept.
Unsupported Statements
Contradictions
Important Omissions
Specific label management details for opioid co-use risk (e.g., lowest effective dosages and minimum durations; follow closely; lower initial dose and titration; advise not to drive/operate heavy machinery until effects determined).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The response accurately reflects the label’s boxed-warning concepts (opioid co-use risk, abuse/misuse/addiction leading to overdose/death, and dependence/withdrawal with life-threatening seizures) and does not include contradictory or misleading information.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Omitted some label-recommended risk mitigation/management specifics for opioid co-use and dependence tapering while still remaining on-topic with the boxed-warning themes.
Suggested Improvement
Include the label’s opioid co-use mitigation elements (lowest effective dose/minimum duration, close monitoring, lower initial dose in patients already on opioids, and driving/operating machinery advice) and taper guidance details to fully mirror the boxed-warning related recommendations.